# BPC-157 FAQ — Common Questions on Research, Regulation, and Prescription Status

> Answers to the most common questions about BPC-157: what it is, what the research shows, why no prescription exists, how 503A compounding status changed in 2026, and what WADA's ban means for athletes.

Regulation, research, pharmacokinetics, and why 'can I get a script?' is a more interesting question than it first appears.

## What is BPC-157 and where does it come from?

BPC-157 is a 15-amino-acid synthetic peptide whose sequence is derived from a partial region of human gastric body protection compound protein — a protein found in human gastric juice. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, and the compound has a molecular weight of 1,419.5 daltons. It was originally identified and studied by a Croatian pharmaceutical research group at the University of Zagreb beginning in the 1990s, and was at one point developed by Pliva Pharmaceuticals under the clinical designation PL-14736. No pharmaceutical-grade licensed drug has resulted from that development program.

## Why is BPC-157 sometimes called 'gastric pentadecapeptide'?

'Pentadecapeptide' simply means a peptide of 15 amino acids — 'penta' (five) plus 'deca' (ten). 'Gastric' refers to its origin: the sequence is derived from a gastric juice protein. You will see 'stable gastric pentadecapeptide BPC 157' in many paper titles from the Zagreb group; this phrasing emphasizes the compound's unusual stability in the gastric environment, which distinguishes it from most peptides of similar size. Research databases also index it as PL 14736, PL-10, and BPC 157 acetate depending on the salt form used.

## Is BPC-157 a natural compound or synthetic?

It is synthetic. The sequence was identified in a naturally occurring protein (human gastric body protection compound), but BPC-157 itself is a synthetic peptide manufactured by solid-phase peptide synthesis. The commercially available research chemical forms are BPC-157 acetate and BPC-157 free base; these are different salt forms of the same peptide. No natural food source or human biochemical process produces the isolated 15-amino-acid sequence in bioavailable quantities.

## What does 'stable in gastric juice' actually mean for research purposes?

Most peptides above a few hundred daltons degrade rapidly when exposed to gastric acid and pepsin. BPC-157 maintains its structural integrity in human gastric juice for more than 24 hours [1]. This stability is what makes oral and intragastric dosing routes plausible in rodent studies — the peptide survives the gastric environment long enough to be absorbed downstream. Whether this translates to sufficient oral bioavailability in humans to produce pharmacological effects is a question the cancelled Phase I pharmacokinetics trial (NCT02637284) would have addressed. The gastric stability is a pharmacological property, not a claim of human efficacy.

## What does current research show about BPC-157 for tissue healing?

The preclinical literature — primarily in rat models — consistently documents accelerated healing of tendon, ligament, muscle, and bone injuries. In rats with surgically detached quadriceps muscles, oral BPC-157 enabled complete muscle-to-bone reattachment confirmed by MRI by day 28; saline controls showed permanent healing failure [5]. In ligament healing studies, both 10 μg/kg and 10 ng/kg intraperitoneal daily doses improved biomechanical tensile strength and collagen organization through 90 days [6]. A 2025 systematic review of 36 studies confirmed consistent functional and structural improvements across these tissue types [4]. Human data consists of three small uncontrolled pilot studies with no randomized comparator — the direction of findings is encouraging; the evidence quality does not yet support clinical conclusions.

## What human clinical data exists for BPC-157?

Three small human pilot studies have been published. First: a retrospective series of 12 patients with chronic knee pain receiving intra-articular BPC-157 injections; 7 of 12 reported pain relief lasting more than 6 months [4]. Second: a 12-patient pilot for interstitial cystitis; all 12 reported 80–100% symptom resolution at 6 weeks after intravesicular injection of 10 mg, and all had previously failed FDA-approved pentosan polysulfate [2]. Third: an IRB-approved (IRCM-2024-402) intravenous safety and pharmacokinetics study in 2 healthy adults who received up to 20 mg IV infusion with no adverse events and no clinically meaningful changes in cardiovascular, hepatic, renal, thyroid, or metabolic biomarkers [2]. A Croatian Phase II trial for inflammatory bowel disease (PL-14736) was conducted with rectal administration and reported as safe, but results were not published in peer-reviewed form [3]. No randomized controlled trial exists.

## Why does most BPC-157 research come from one group in Zagreb?

The BPC-157 literature is heavily concentrated in publications from Predrag Sikiric, Sven Seiwerth, and their colleagues at the University of Zagreb. This is partly historical — the group did the foundational work beginning in the late 1980s and 1990s, established the animal models, and has published continuously since. It also reflects a common pattern in research on compounds with limited commercial backing: when there is no major pharmaceutical company funding independent replication, the original group often remains the primary publisher. Independent analysis exists — the 2025 systematic reviews by McGuire et al. and Vasireddi et al. were conducted by authors at US academic medical centers — but they analyzed the Zagreb-group data rather than generating new primary data. Whether future independent replication confirms the Zagreb findings is the central open question in the field.

## Is BPC-157 related to TB-500 (Thymosin Beta-4 Fragment)?

BPC-157 and TB-500 (a synthetic fragment of Thymosin Beta-4) are distinct compounds with distinct sequences and mechanisms. BPC-157 acts via VEGFR2/Akt-eNOS/FAK-paxillin angiogenesis and fibroblast migration signaling; TB-500 acts primarily through actin-binding and lamellipodia formation. They have been co-studied in musculoskeletal injury models in the research literature because their mechanisms are potentially complementary — one driving vascularization, the other driving cell motility — but they are not the same compound and should not be treated as interchangeable.

## How long does BPC-157 stay in the body?

The pharmacokinetic study by He et al. established a plasma half-life under 30 minutes in both rat and beagle dog models following IV and IM administration. Tmax was 3 minutes in rats and 6.3–8.7 minutes in dogs. Intramuscular bioavailability was 14–19% in rats and 45–51% in dogs. The compound is metabolized hepatically to proline and small peptide fragments, with approximately 16–18% urinary recovery [1]. The sub-30-minute half-life is notable because preclinical studies have documented functional effects sustained for weeks to months after single or short-course treatment. The mechanism that reconciles rapid plasma clearance with durable preclinical effects is not definitively established in the published literature.

## What is BPC-157's regulatory and compounding status in the United States as of 2026?

As of mid-2026, BPC-157 occupies regulatory limbo. It is not on the FDA's 503A Category 1 Bulks List (which would permit 503A compounding pharmacies to prepare it). It was on Category 2 (which prohibited 503A compounding) from September 2023 until April 2026, when the FDA published Federal Register notice 2026-07361 removing it from Category 2 after the original 503A nominators formally withdrew the nomination. Removal from Category 2 does not authorize compounding — it simply means there is no specific prohibition at this moment. The substance remains classified as an unapproved new drug under the FDCA. A Pharmacy Compounding Advisory Committee (PCAC) meeting to evaluate BPC-157 (free base and acetate) for potential Category 1 inclusion is scheduled for July 23–24, 2026 [3].

## Can a physician legally prescribe BPC-157?

No — not in the way the word 'prescribe' normally works. Because BPC-157 is not FDA-approved for any indication, 'off-label prescribing' — the practice that governs how licensed physicians use approved drugs for unapproved uses — is legally inapplicable. A physician administering BPC-157 outside an FDA-authorized Investigational New Drug (IND) framework is administering an unapproved new drug, which carries legal and liability implications distinct from off-label prescribing. A physician can apply for and operate under an IND — which requires FDA approval and IRB oversight — to administer BPC-157 in a research context. That is a research pathway, not a prescription pathway [3].

## What are the legitimate research pathways to investigate BPC-157 in humans?

Three FDA-recognized pathways exist for human investigation of unapproved compounds. First, an Investigational New Drug (IND) application, which allows clinical trials under FDA and IRB oversight — this is the standard path for drug development. Second, an Expanded Access (Compassionate Use) IND for patients with serious conditions lacking alternatives, which also requires FDA approval and a sponsor/manufacturer supply chain. Third, IRB-approved observational or safety pilot studies — the framework under which Lee and Burgess conducted the 2025 IV safety and pharmacokinetics study (IRCM-2024-402) in 2 healthy adults [2]. ClinicalTrials.gov registration (NCT02637284) was attempted for a Phase I pharmacokinetics study in 2015, but that trial was cancelled in 2016 before completion [3].

## What is the difference between 503A compounding and investigational use of BPC-157?

503A compounding pharmacies prepare customized medications for individual patients based on a valid prescription. For a 503A pharmacy to compound BPC-157, the substance would need to appear on the Category 1 Bulks List — which it currently does not. Investigational use, by contrast, occurs under an IND application submitted to the FDA; it is not prescription-based and requires IRB oversight and FDA authorization. The two pathways are parallel, not sequential: Category 1 listing would enable prescription compounding; IND authorization enables research administration. The July 2026 PCAC meeting addresses the former [3].

## What happened with the FDA's Category 2 designation and what comes next?

BPC-157 was placed in Category 2 of the FDA's 503A Interim Bulks Guidance in September 2023, effectively prohibiting compounding pharmacies from preparing it for human use. In February 2026, HHS Secretary announcements signaled a reconsideration of peptide compounding restrictions. On April 15, 2026, the FDA published Federal Register notice 2026-07361, removing BPC-157 from Category 2 after the original nominators formally withdrew the substance from the 503A evaluation process. The removal does not authorize compounding — the default status of an unapproved new drug under the FDCA applies. The next milestone is the scheduled PCAC meeting on July 23–24, 2026, at which the committee will evaluate BPC-157 free base and BPC-157 acetate for potential 503A Category 1 inclusion [3]. PCAC recommendations are advisory; FDA rulemaking would follow if the committee recommends inclusion.

## Why is BPC-157 banned by WADA and what does that mean for athletes?

The World Anti-Doping Agency placed BPC-157 on the Prohibited List under Section S0 — Non-Approved Substances, effective January 1, 2022. S0 prohibits any pharmacological substance not approved by a regulatory authority for human therapeutic use, regardless of whether it is a performance-enhancing agent in the conventional sense. BPC-157 is prohibited at all times in all sports under the WADA Code. Competitive athletes subject to WADA rules who are detected using BPC-157 face the standard anti-doping sanctions regardless of therapeutic intent or whether the use was supervised by a physician. The WADA ban does not reflect a determination that BPC-157 enhances athletic performance; it reflects the general prohibition on non-approved substances.

## What enforcement actions have occurred related to BPC-157?

The most significant enforcement action in the compounding space involved Tailor Made Compounding LLC, which the DOJ prosecuted for distributing BPC-157 and related unapproved peptides. The case resulted in a $1.79 million forfeiture and served as an industry-wide enforcement signal to compounding pharmacies. The prosecution was premised on BPC-157's status as an unapproved new drug under the FDCA — the same legal basis that continues to apply regardless of the April 2026 Category 2 removal. Removal from Category 2 removes the specific compounding prohibition; it does not remove the underlying unapproved-new-drug status that the Tailor Made prosecution used [3].

## What would it mean for Category 1 listing to occur after the July 2026 PCAC meeting?

If the PCAC recommends BPC-157 for Category 1 inclusion at the July 2026 meeting, and the FDA subsequently completes rulemaking to add it to the Category 1 list, 503A compounding pharmacies would be able to prepare BPC-157 for individual patients based on a valid prescription. This would not make BPC-157 an 'approved drug' — the FDA approval pathway (New Drug Application) is separate from 503A compounding authorization. It would, however, create a legal route by which licensed physicians could write prescriptions for compounded BPC-157 that pharmacies could fill. Category 1 listing is advisory; the timeline from PCAC recommendation to final rulemaking is uncertain.

---

A literature digest drawn from peer-reviewed sources — not a clinic, not a vendor, not a prescription.